MP Group: Idiopathic Pulmonary Fibrosis (IPF)

It’s a pleasure to share with you our latest report on Idiopathic Pulmonary Fibrosis (IPF)—a field rapidly evolving amidst unmet needs, increasing prevalence, and a surge in innovation. This report delivers a strategic view of the clinical, commercial, and R&D shifts shaping the IPF landscape, tailored for leaders driving decisions in respiratory and rare diseases. Key highlights of the presentation are: The evolving treatment paradigm beyond antifibrotics—toward targeted, multi-pathway, and regenerative therapies Strategic insights on Phase 2 & 3 assets—differentiation…

Continue ReadingMP Group: Idiopathic Pulmonary Fibrosis (IPF)

MP Group: Latest analysis on The next wave of biosimilars

Our latest analysis on The next wave of biosimilars, highlighting a significant opportunity as biologics $150B approach patent expiry in this decade. With biosimilars capturing over 50%+ market share within three years of launch, the sector is set for continued expansion. By 2032, 118 biologics worth ~$235B will lose exclusivity, yet only a fraction currently have biosimilars in clinical development — presenting a significant untapped market. Strategic partnerships will be critical to sharing the high costs, navigating the regulatory hurdles,…

Continue ReadingMP Group: Latest analysis on The next wave of biosimilars

MP Group: Inflammatory Bowel Disease Therapy Area Landscape: Breaking New Ground in Treatment

It is our pleasure to share with you our latest report on Inflammatory Bowel Disease Therapy Area Landscape: Breaking New Ground in Treatment. The report provides market and competitive analysis of evolving therapeutic landscape of IBD while anticipating how the future treatment paradigm is likely to evolve. Key Highlights of the Deck - Assessment of the evolving treatment paradigm: Explore the market trends and transition from conventional step-up approaches to a more aggressive top-down strategy Current landscape of targeted therapies: Insights into the…

Continue ReadingMP Group: Inflammatory Bowel Disease Therapy Area Landscape: Breaking New Ground in Treatment

MP Global: Global Landscape of GLP Tox Outsourcing – A booming frontier for CROs

It is our pleasure to share with you our Global Landscape of GLP Tox Outsourcing – A booming frontier for CROs. GLP Tox outsourcing market is expected to touch ~$13B by 2028, driven by expanding R&D pipeline, including the rise in complex therapies. Tox testing, especially GLP Tox, remains one of the most commonly outsourced activities by biopharma. To cater to the evolving needs of the biopharma industry, the CROs will need to expand to more specialized tox offerings, differentiated animal…

Continue ReadingMP Global: Global Landscape of GLP Tox Outsourcing – A booming frontier for CROs

Pharmaphorum: Digital twins in healthcare and drug discovery: From idea to success stories

The term "digital twins" has its origins in engineering and computer science, where it refers to a virtual replica of a physical object or system. Simply put, it is a sophisticated, dynamic, real-time digital representation of a physical entity created using advanced computational models. The sole purpose of these models is to simulate how an object or process would change under a specific scenario. The aerospace industry has been particularly successful in deploying digital twins, where real-time data is fed…

Continue ReadingPharmaphorum: Digital twins in healthcare and drug discovery: From idea to success stories

MP Group: Outlook on Global Medical Communications Outsourcing

Pleasure to share with you our Outlook on ‘Global Medical Communications Outsourcing’. Medical communications is becoming an integral part of drug development and commercialization strategy, owing to the pursuit of innovative and complex therapies, articulation of medical and economic benefits and adopting a patient-centric approach. As a result, the medical communications outsourcing market, from a current base of ~$2B in 2023, is expected to reach ~$8B by 2026, growing at a CAGR of 18%. The evolution of technology and omnichannel…

Continue ReadingMP Group: Outlook on Global Medical Communications Outsourcing

MP Group: Outlook on Growth of the US biosimilars market – Key trends and opportunities

Pleasure to share our Outlook on Growth of the US biosimilars market – Key trends and opportunities. Historically, the US biosimilars market has posed several challenges restricting its penetration. Ambiguous regulatory guidelines contributing to high cost and timelines for development, patent dance causing uncertainties with launch timelines and barriers posed by the innovators limiting the market penetration – all of these led to the biosimilars market only dominated by the innovator companies. However, over the last 3-5 years, the landscape…

Continue ReadingMP Group: Outlook on Growth of the US biosimilars market – Key trends and opportunities

Biospectrum: How Deep Tech is Powering India’s Biopharma Future

Advancements in cutting-edge innovative technologies and the increasing availability of data have enabled various domains of the biotech and pharma industries to leverage resourceful approaches in driving progress, maintaining competitive advantage and accomplishing the ultimate goal of improved patient outcomes. Deep tech ventures, also referred to as hard tech as opposed to regular digital platforms, primarily focus on the fundamental core issues of a business. For India to become an ‘innovation hub’, with concerted transformative efforts of leaders and experts…

Continue ReadingBiospectrum: How Deep Tech is Powering India’s Biopharma Future

Drug Discovery and AI: overview of the main investments and partnerships of 2023

Artificial intelligence plays an increasing role in the discovery of new drugs. Which start-ups specializing in biotechnology have raised funds? For which therapeutic specialties or types of molecules? Which pharmaceutical laboratories support them? In partnership with Amandeep Singh, project manager at MP Advisors, mind Health has identified and analyzed the main announcements in the field in 2023. hile the search for new drugs is a long and expensive process, subject to high uncertainty, technology is playing an increasing role. Artificial intelligence (AI),…

Continue ReadingDrug Discovery and AI: overview of the main investments and partnerships of 2023

MP Group: Trends in the Bio-IT Services Industry

We are pleased to share with you our latest industry insights report titled Trends in the Bio-IT Services Industry. This report is based on insights derived from conversations with 50 CEOs of small to mid-sized companies providing life sciences-specific IT services across the R&D value chain. Digital transformation has become a top priority across the life sciences leadership, fuelling the growth of Bio-IT solutions companies at a remarkable pace. Over the last few years, the Bio-IT services companies are witnessing…

Continue ReadingMP Group: Trends in the Bio-IT Services Industry